Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir

AIDS

Volumn 16, Issue 14, 2002, Pages 1964-1966

  Valer, Luisa ^a   De Mendoza, Carmen ^a   De Requena, Daniel González ^a   Labarga, Pablo ^b   García Henarejos, Adolfo ^c   Barreiro, Pablo ^a   Guerrero, Francisca ^d   Vergara, Antonio ^e   Soriano, Vincent ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL SAN PEDRO   (Spain)

^c Hospital Santa Maria Rosell   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^e HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS MUTATION;

CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MICROBIAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MULTICENTER STUDIES; MUTATION; PLASMA; PROSPECTIVE STUDIES; RNA, VIRAL; SAQUINAVIR;

EID: 0037183919     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200209270-00016     Document Type: Article

References (22)

1. International AIDS Society - USA Resistance Testing Panel and HIV inSite. Antiretroviral resistance mutations. HIV Clin Trials 2001, 2:346-355.
2. Hirsch M, Brun-Vezinet F, D'Aquila R, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society - USA Panel. JAMA 2000, 283:2417-2426.
3. Hsu A, Granneman G, Cao G, et al. Pharmacokinetic interactions between two HIV protese inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998, 63:453-464.
4. Veldkamp A, Van Heeswijk R, Mulder J, et al. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1 infected individuals. J Acquired Immune Defic Syndr 2001, 27:344-349.
5. Buss N, Snell P, Bock J, Hsu A, Jorga K. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. J Clin Pharmacol 2001, 52:255-264.
6. Michelet C, Ruffault A, Sébille V, et al. Ritonavir-saquinavir dual PI compared to ritonavir alone in HIV-infected patients. Antimicrob Agents Chemother 2001, 45:3393-3402.
7. Eron J, Haubrich R, Lang W, et al. A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir or saquinavir. J Acquired Immune Defic Syndr 2001, 26:458-461.
8. Deeks S, Grant R, Beatty G, et al. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 1998, 12:F97-F102.
9. Tebas P, Patick A, Kane E, et al. Virologic response to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS 1999, 13:F23-F28.
10. Rodríguez-Rosado R, Soriano V, Barreiro P, Dona C, González-Lahoz J. What dual protease inhibitor combination for salvage therapies? AIDS 1999, 13:2180-2181.
11. Chavanet P, Piroth M, Grappin M, et al. Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients. HIV Clin Trials 2001, 2:408-412.
12. Baxter J, Mayers D, Wentworth D, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000, 14:F89-F93.
13. Ross L, Liao Q, Gao H, et al. Impact of HIV-1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy. AIDS Res Hum Retroviruses 2001, 17:1379-1385.
14. Zolopa A, Shaper R, Warford A, et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients whom previous response inhibitors therapy had failed. Ann Intern Med 1999, 131:813-821.
15. Pellegrin I, Breilh D, Birac V, et al. Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens. Ther Drug Monitor 2001, 23:332-340.
16. Harrigan R, Hertogs K, Verbiest W, et al. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 1999, 13:1863-1871.
17. Piketty C, Race E, Castiel P, et al. Phenotypic resistance to protease inhibitors in patients who fail on HAART predicts the outcome at 48 weeks of a five-drug combination including ritonavlr, saquinavir and efavirenz. AIDS 2000, 14:626-628.
18. De Mendoza C, Martin-Carbonero L, Barreiro P, et al. Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. HIV Clin Trials 2002, 3:304-309.
19. Telenti A, Bleiber G, Ledergerber B, Kauffmann D. Heterogeneity in the response to antiretroviral therapy. AIDS Reviews 1999, 1:147-155.
20. Calvez V, Cohen-Codar Marcelin A, et al. Efficacy of lopinavir/ritonavir in 104 multiple PI-experienced patients according to mutational patterns: data from French ATU program. In: 8th European Conference on Clinical Aspects and Treatment of HIV/Athens, 2001 [Abstract 234].
21. Ngo P, Cohen-Codar I, Boer F, et al. Study of the initial response to Kaletra in HIV treatment-experienced patients: the ATU preregistrational cohort in France. In: 8th European Conference on Clinical Aspects and Treatment of HIV. Athens, 2001 [Abstract 236].
22. Barreiro P, Dona C, Castilla J, Soriano V. Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on HAART. AIDS 1999, 13:525-526.